Clinical Trials Logo

Ovarian Cancer clinical trials

View clinical trials related to Ovarian Cancer.

Filter by:

NCT ID: NCT05446545 Recruiting - Ovarian Cancer Clinical Trials

Bespoke ctDNA Assay for Recurrence and Treatment Response Monitoring in Advanced Epithelial Ovarian Cancer

EOC
Start date: September 1, 2021
Phase:
Study type: Observational

This prospective observational study is to assess the dynamics of circulating tumor DNA (ctDNA) in patients with advanced epithelial ovarian cancer (EOC) undergoing surgery, adjuvant chemotherapy, followed by poly adenosine diphosphate-ribose polymerase (PARP) inhibitors until disease progression or the end of the study. All patients will be closely monitored throughout the course of disease by a tumor-informed bespoke ctDNA assay as well as traditional methods of surveillance, such as CA125 and imaging. This study may provide preliminary evidence for ctDNA-guided treatment decisions in future clinical practice.

NCT ID: NCT05446298 Recruiting - Ovarian Cancer Clinical Trials

ONC-392 and Pembrolizumab in Platinum Resistant Ovarian Cancer

PRESERVE-004
Start date: December 22, 2022
Phase: Phase 2
Study type: Interventional

This is a study to test the safety and efficacy with the combination of a next generation anti-CTLA-4 antibody, ONC-392, and anti-PD-1 antibody, pembrolizumab, in platinum resistant ovarian cancer patients.

NCT ID: NCT05445778 Recruiting - Ovarian Cancer Clinical Trials

Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Ovarian, Fallopian Tube, or Peritoneal Cancer (GLORIOSA)

Start date: December 27, 2022
Phase: Phase 3
Study type: Interventional

GLORIOSA is a Phase 3 multicenter, open label study designed to evaluate the safety and efficacy of mirvetuximab Soravtansine as maintenance therapy in participants with platinum-sensitive ovarian, primary peritoneal or fallopian tube cancers with high folate receptor-alpha (FRα) expression.

NCT ID: NCT05431530 Recruiting - Quality of Life Clinical Trials

Assessment of Quality of Life After Low Anterior Resection During Cytoreductive Surgery for Advanced Ovarian Cancer

LAPSODY
Start date: June 22, 2022
Phase:
Study type: Observational

This study aims to evaluate the incidence of low anterior resection syndrome and quality of life after cytoreductive surgery for advanced ovarian cancer patients.

NCT ID: NCT05430906 Recruiting - Ovarian Cancer Clinical Trials

AK104 Combined With Chemotherapy as Neoadjuvant Treatment for Advanced Ovarian Cancer

Start date: November 25, 2022
Phase: Phase 2
Study type: Interventional

Previous studies have suggested that immunotherapy combined with chemotherapy as neoadjuvant treatment for ovarian cancer may have a synergistic effect and a manageable safety profile. AK104 is a bispecific antibody targeting PD-1 and CTLA-4. Therefore, this study aimed to evaluate the efficacy and safety of AK104 combined with chemotherapy as the neoadjuvant treatment for advanced ovarian cancer.

NCT ID: NCT05429970 Recruiting - Ovarian Cancer Clinical Trials

A Study Comparing Perioperative Stress Reduction vs. Standard of Care in Ovarian Cancer (PRESERVE)

Start date: June 17, 2022
Phase: N/A
Study type: Interventional

The purpose of this study is to see if propranolol and etodolac along with mind-body resilience training/MBRT and music therapy help participants who are experiencing physiological stress before, during, and after primary debulking surgery/PDS or IDS and also if it's better than the standard-of-care approach (no intervention for reducing stress).

NCT ID: NCT05427487 Recruiting - Colorectal Cancer Clinical Trials

Study of Intratumoral IVX037 in Patients With Advanced or Metastatic Solid Tumours

Start date: February 17, 2023
Phase: Phase 1
Study type: Interventional

This is a Phase 1 open-label, non-randomized, multi-center clinical trial of intratumoral IVX037 in people with micro satellite-stable (MSS) colorectal or gastroesophageal cancer metastatic to liver, or advanced ovarian cancer.

NCT ID: NCT05427214 Recruiting - Lung Cancer Clinical Trials

Imaging Study on Halcyon 4.0 System for Patients Receiving Radiation Therapy

Dragon
Start date: August 19, 2022
Phase: N/A
Study type: Interventional

This prospective imaging study is evaluating the feasibility of using the Halcyon 4.0 radiotherapy system for radiation therapy planning in patients with cancer. The Halcyon 4.0 system has been engineered to decrease the image acquisition time and the radiation exposure, but the system has not yet been clinically validated for use in radiation planning. This pilot study will evaluate images obtained on the Halcyon 4.0 system to assess if the quality is sufficient for radiation treatment plan construction.

NCT ID: NCT05420545 Recruiting - Ovarian Cancer Clinical Trials

A Clinical Study of CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Solid Tumors

Start date: December 31, 2021
Phase: Phase 1
Study type: Interventional

This is a phase I clinical study to evaluate the safety and tolerability of CAR-T in patients with CD70-positive advanced/metastatic solid tumors, and to obtain the maximum tolerated dose of CAR-T and phase II Recommended dose.

NCT ID: NCT05415527 Recruiting - Ovarian Carcinoma Clinical Trials

Evaluation of Pretreatment Sarcopenia in Patients With Inoperable High-grade Ovarian Carcinoma as Part of Optimised Management

OPTIMOVA
Start date: June 11, 2022
Phase: N/A
Study type: Interventional

Prospective, monocentric study evaluating the presence of sarcopenia prior to neoadjuvant chemotherapy and during chemotherapy as part of optimised management.